High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results